Cargando…

Monocyte programming by cancer therapy

Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-derive suppressor cells (MDSC). Monocytes-derived cells orchestrate immune reactions in tumor microenviro...

Descripción completa

Detalles Bibliográficos
Autores principales: Patysheva, Marina, Frolova, Anastasia, Larionova, Irina, Afanas'ev, Sergey, Tarasova, Anna, Cherdyntseva, Nadezhda, Kzhyshkowska, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631446/
https://www.ncbi.nlm.nih.gov/pubmed/36341366
http://dx.doi.org/10.3389/fimmu.2022.994319
_version_ 1784823820550406144
author Patysheva, Marina
Frolova, Anastasia
Larionova, Irina
Afanas'ev, Sergey
Tarasova, Anna
Cherdyntseva, Nadezhda
Kzhyshkowska, Julia
author_facet Patysheva, Marina
Frolova, Anastasia
Larionova, Irina
Afanas'ev, Sergey
Tarasova, Anna
Cherdyntseva, Nadezhda
Kzhyshkowska, Julia
author_sort Patysheva, Marina
collection PubMed
description Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-derive suppressor cells (MDSC). Monocytes-derived cells orchestrate immune reactions in tumor microenvironment that control disease outcome and efficiency of cancer therapy. Four major types of anti-cancer therapy, surgery, radiotherapy, chemotherapy, and most recent immunotherapy, affect tumor-associated macrophage (TAM) polarization and functions. TAMs can also decrease the efficiency of therapy in a tumor-specific way. Monocytes is a major source of TAMs, and are recruited to tumor mass from the blood circulation. However, the mechanisms of monocyte programming in circulation by different therapeutic onsets are only emerging. In our review, we present the state-of-the art about the effects of anti-cancer therapy on monocyte progenitors and their dedifferentiation, on the content of monocyte subpopulations and their transcriptional programs in the circulation, on their recruitment into tumor mass and their potential to give origin for TAMs in tumor-specific microenvironment. We have also summarized very limited available knowledge about genetics that can affect monocyte interaction with cancer therapy, and highlighted the perspectives for the therapeutic targeting of circulating monocytes in cancer patients. We summarized the knowledge about the mediators that affect monocytes fate in all four types of therapies, and we highlighted the perspectives for targeting monocytes to develop combined and minimally invasive anti-cancer therapeutic approaches.
format Online
Article
Text
id pubmed-9631446
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96314462022-11-04 Monocyte programming by cancer therapy Patysheva, Marina Frolova, Anastasia Larionova, Irina Afanas'ev, Sergey Tarasova, Anna Cherdyntseva, Nadezhda Kzhyshkowska, Julia Front Immunol Immunology Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-derive suppressor cells (MDSC). Monocytes-derived cells orchestrate immune reactions in tumor microenvironment that control disease outcome and efficiency of cancer therapy. Four major types of anti-cancer therapy, surgery, radiotherapy, chemotherapy, and most recent immunotherapy, affect tumor-associated macrophage (TAM) polarization and functions. TAMs can also decrease the efficiency of therapy in a tumor-specific way. Monocytes is a major source of TAMs, and are recruited to tumor mass from the blood circulation. However, the mechanisms of monocyte programming in circulation by different therapeutic onsets are only emerging. In our review, we present the state-of-the art about the effects of anti-cancer therapy on monocyte progenitors and their dedifferentiation, on the content of monocyte subpopulations and their transcriptional programs in the circulation, on their recruitment into tumor mass and their potential to give origin for TAMs in tumor-specific microenvironment. We have also summarized very limited available knowledge about genetics that can affect monocyte interaction with cancer therapy, and highlighted the perspectives for the therapeutic targeting of circulating monocytes in cancer patients. We summarized the knowledge about the mediators that affect monocytes fate in all four types of therapies, and we highlighted the perspectives for targeting monocytes to develop combined and minimally invasive anti-cancer therapeutic approaches. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9631446/ /pubmed/36341366 http://dx.doi.org/10.3389/fimmu.2022.994319 Text en Copyright © 2022 Patysheva, Frolova, Larionova, Afanas'ev, Tarasova, Cherdyntseva and Kzhyshkowska https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Patysheva, Marina
Frolova, Anastasia
Larionova, Irina
Afanas'ev, Sergey
Tarasova, Anna
Cherdyntseva, Nadezhda
Kzhyshkowska, Julia
Monocyte programming by cancer therapy
title Monocyte programming by cancer therapy
title_full Monocyte programming by cancer therapy
title_fullStr Monocyte programming by cancer therapy
title_full_unstemmed Monocyte programming by cancer therapy
title_short Monocyte programming by cancer therapy
title_sort monocyte programming by cancer therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631446/
https://www.ncbi.nlm.nih.gov/pubmed/36341366
http://dx.doi.org/10.3389/fimmu.2022.994319
work_keys_str_mv AT patyshevamarina monocyteprogrammingbycancertherapy
AT frolovaanastasia monocyteprogrammingbycancertherapy
AT larionovairina monocyteprogrammingbycancertherapy
AT afanasevsergey monocyteprogrammingbycancertherapy
AT tarasovaanna monocyteprogrammingbycancertherapy
AT cherdyntsevanadezhda monocyteprogrammingbycancertherapy
AT kzhyshkowskajulia monocyteprogrammingbycancertherapy